NCT03441100已完成1 期
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 6
- 主要终点
- Incidence of adverse events (AE)
研究概览
简要总结
The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
详细描述
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA202 product.
MANUFACTURING: IMA202 product will be made from the patient's white blood cells.
TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA202 product infusion to improve the duration of time that IMA202 product stays in the body. The patient will be admitted to the hospital during the treatment.
After the IMA202 product infusion, a low dose of IL-2 will be given twice daily for a period of time.
Patients will be closely monitored for safety and for a total of 3 years post IMA202 infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed advanced and/or metastatic solid tumor
- •Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •HLA phenotype positive for the study
- •Measurable disease and accessible to biopsy
- •Adequate pulmonary function per protocol
- •Acceptable organ and bone marrow function per protocol
- •Acceptable coagulation status per protocol
- •Adequate hepatic function per protocol
- •Adequate renal function per protocol
- •Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen
- •Life expectancy more than 3 months
- •Confirmed availability of production capacities for IMA202 product
- •Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.
- •For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6
- •IMA202 product must have passed all of the release tests
- •Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA202
- •Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA202
- •Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is required within 6 months of study entry
- •The patient must have recovered from any side effects of prior therapy to Grade 1 or lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo) prior to lymphodepletion. As determined by the investigator, the patient may still be eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such toxicities are not anticipated to worsen with the lymphodepletion therapy
排除标准
- •History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
- •Solid tumors with low likelihood of tumor biomarker expression per protocol
- •Pregnant or breastfeeding
- •Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.
- •History of cardiac conditions as per protocol
- •Prior stem cell transplantation or solid organ transplantation
- •Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
- •History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), IL-2, or any of the rescue medications
- •History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
- •HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at the most recent laboratory report. Patients with both HBV and HCV infections will be excluded from screening
- •Patients with a history of HCV infection and with an undetectable viral load per the most recent laboratory report and/or completed anti-HCV treatment but are HCV antibody positive are permitted.
- •History of treated HBV infection is permitted if the viral load is undetectable per the most recent laboratory report. Note: HCC patients with controlled HBV infection, as defined by resolved (anti-hepatitis B surface antigen [HBs-Ag] antibody (Ab) negative, anti-core antigen [HBc Ag] Ab positive) or chronic stable (anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients with active HBV infection who are not on anti-HBV treatment will be excluded.
- •Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA202 treatment
- •Patients with any active viral infection
- •Patients with active brain metastases
- •NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks.
- •Treatment with protocol-defined excluded treatments, medical devices, and/or procedures per protocol
- •Concurrent participation in an interventional part of another clinical trial.
研究组 & 干预措施
Experimental: IMA202 Product
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.
- Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2
干预措施: IMA202 Product (Drug)
Experimental: IMA202 Product
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.
- Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2
干预措施: IMADetect® (Device)
结局指标
主要结局
Incidence of adverse events (AE)
时间窗: up to 3 years post treatment
次要结局
- Persistence of T-cells(up to 3 years post treatment)
- Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)(up to 12 months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)Solid TumorRecurrent Solid TumorsRefractory Solid TumorsCancerNCT03247309Immatics US, Inc.7
招募中
1 期
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRefractory CancerRecurrent CancerSolid Tumor, AdultCancerNCT03686124Immatics US, Inc.375
已完成
1 期
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative ColitisModerately Active Ulcerative ColitisNCT00729872ActoGeniX N.V.60
已完成
1 期
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML PatientsMyelodysplastic Syndromes (MDS)Acute Myeloid Leukaemia (AML)NCT02550535Cell Medica Ltd3
终止
1 期
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria VaccineMalariaNCT01024686Seattle Children's Hospital6